1. Home
  2. INTS vs ABLV Comparison

INTS vs ABLV Comparison

Compare INTS & ABLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • ABLV
  • Stock Information
  • Founded
  • INTS 2012
  • ABLV 2015
  • Country
  • INTS United States
  • ABLV China
  • Employees
  • INTS N/A
  • ABLV N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • ABLV
  • Sector
  • INTS Health Care
  • ABLV
  • Exchange
  • INTS Nasdaq
  • ABLV Nasdaq
  • Market Cap
  • INTS 33.4M
  • ABLV 38.1M
  • IPO Year
  • INTS 2023
  • ABLV N/A
  • Fundamental
  • Price
  • INTS $2.23
  • ABLV $0.87
  • Analyst Decision
  • INTS Strong Buy
  • ABLV
  • Analyst Count
  • INTS 3
  • ABLV 0
  • Target Price
  • INTS $8.50
  • ABLV N/A
  • AVG Volume (30 Days)
  • INTS 26.6K
  • ABLV 73.4K
  • Earning Date
  • INTS 03-13-2025
  • ABLV 01-01-0001
  • Dividend Yield
  • INTS N/A
  • ABLV N/A
  • EPS Growth
  • INTS N/A
  • ABLV N/A
  • EPS
  • INTS N/A
  • ABLV N/A
  • Revenue
  • INTS N/A
  • ABLV $130,087,189.00
  • Revenue This Year
  • INTS N/A
  • ABLV N/A
  • Revenue Next Year
  • INTS N/A
  • ABLV N/A
  • P/E Ratio
  • INTS N/A
  • ABLV N/A
  • Revenue Growth
  • INTS N/A
  • ABLV N/A
  • 52 Week Low
  • INTS $1.50
  • ABLV $0.55
  • 52 Week High
  • INTS $5.94
  • ABLV $3.10
  • Technical
  • Relative Strength Index (RSI)
  • INTS 49.26
  • ABLV 37.65
  • Support Level
  • INTS $1.84
  • ABLV $0.80
  • Resistance Level
  • INTS $2.27
  • ABLV $1.07
  • Average True Range (ATR)
  • INTS 0.28
  • ABLV 0.17
  • MACD
  • INTS -0.01
  • ABLV -0.03
  • Stochastic Oscillator
  • INTS 56.36
  • ABLV 19.06

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

Share on Social Networks: